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ABSTRACT
Purpose. To investigate the prognostic value of multiple
cell cycle-associated proteins in a large series of stage II
and III colon cancers.
Methods. From formalin-fixed, paraffin-embedded tumor
samples of 386 patients with stage II and III colon cancer,
DNA was isolated and tissue microarrays were constructed.
Tissue microarray slides were immunohistochemically
stained for p21, p27, p53, epidermal growth factor recep-
tor, Her2/Neu, b-catenin, cyclin D1, Ki-67, thymidylate
synthase, and Aurora kinase A (AURKA). Polymerase
chain reaction–based microsatellite instability analysis was
performed to allow for stratification of protein expression
by microsatellite instability status.
Results. Overall, low p21, high p53, low cyclin D1, and
high AURKA expression were significantly associated with
recurrence (P = 0.01, P \ 0.01, P = 0.04, and P \ 0.01,
respectively). In stage II patients who did not receive
adjuvant chemotherapy (n = 190), significantly more
recurrences were observed in case of low-p21 and high-
p53-expressing tumors (P \ 0.01 and P = 0.03, respec-
tively). In stage III patients who did not receive
chemotherapy, high p53 expression was associated with
recurrence (P = 0.02), and in patients who received che-
motherapy, high AURKA expression was associated with
relapse (P \ 0.01). In patients with microsatellite stable
tumors, high levels of p53 and AURKA were associated
with recurrence (P = 0.01 and P \ 0.01, respectively).
Multivariate analysis showed p21 (odds ratio 1.6, 95%
confidence interval 0.9–2.8) and AURKA (odds ratio 2.7,
95% confidence interval 1.3–5.6) to be independently
associated with disease recurrence.
Conclusions. p21, p53, cyclin D1, and AURKA could
possibly be used as prognostic markers to identify colon
cancer patients with high risk of disease recurrence.
Currently, the tumor, node, metastasis (TNM) staging
system, developed by the American Joint Committee on
Cancer (AJCC) and the Union for International Cancer
Control (UICC), is the primary method for assessing
prognosis for individual patients).1 This classification
forms the basis for therapeutic decision making in clinical
practice. Adjuvant 5-fluorouracil-based chemotherapy has
been found to increase 5-year survival in stage III colon
cancer patients from 51% to 64%.2 However, no con-
vincing evidence exists for a beneficial effect of chemo-
therapy in stage II patients; 20–30% of these patients will
develop recurrent disease.3,4
Molecular markers reflecting tumor biology may allow
for identifying subgroups of patients with high risk of
disease recurrence, and may indicate who will or will not
benefit from adjuvant therapy.
Proliferation and cell cycle control are central processes
in the biology of cancer.5 Yet the exact prognostic value of
cell cycle-associated markers in colon cancer remains
unclear. Numerous studies on these markers have been pub-
lished, but the majority of these are based on relatively small,
heterogeneous series of patients and lack microsatellite
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instability (MSI) analysis and multivariate analysis. The aim
of the present study was to investigate the prognostic value
of multiple cell cycle-associated proteins in a large series of
stage II and III colon cancer patients with determined MSI
status.
The panel of markers studied consisted of proteins regu-
lating cell cycle arrest and checkpoint control [p21
(CDKN1A), p27 (CDKN1B), p53 (TP53)], transmembrane
and intracellular signaling proteins [epidermal growth factor
receptor (EGFR), Her2/Neu (ERBB2), b-catenin (CTNNB1)],
proteins involved in progression of the cell cycle to M-phase
[cyclin D1 (CCND1), Ki-67 (MKI67)], and thymidylate
synthetase (TS, TYMS) and Aurora kinase A (AURKA).
PATIENTS AND METHODS
Between 1996 and 2005, a total of 386 patients under-
went surgical resection for colon cancer, classified as TNM
stage II (T3–4, N0, M0) or III (T1–4, N1–2, M0) according
to the TNM staging system by the AJCC and UICC.6 Data
were collected from clinical and histopathology reports.
Patients with positive resection margins and those who
were lost to follow-up or who died within 3 months after
surgery were excluded. Disease recurrence was defined as
either local tumor recurrence or distant metastasis, diag-
nosed by CT imaging and/or histopathology.
Tissue Microarray
Tissue microarrays (TMAs) were constructed as
described previously.7 Briefly, formalin-fixed, paraffin-
embedded tissue blocks of colon cancer resection speci-
mens were used as donor blocks. Six tissue cylinders with a
diameter of 0.6 mm were punched from morphologically
representative tissue areas of each donor block and trans-
ferred into the recipient TMA paraffin blocks.
Immunohistochemistry
Immunohistochemistry was performed on 4-lm-thick
sections from the TMA blocks. Paraffin was removed from
tissue sections with xylene and the sections rehydrated.
Endogenous peroxidase activity was quenched with 0.3%
hydrogen peroxide in methanol. For antigen retrieval, the
samples were immersed in 10 mM citrate buffer solution
and heated in a microwave. Slides were incubated with
antibodies specific for p21 (Waf1/Cip1, clone SX118,
Dako, Heverlee, Belgium, dilution 1/25), p27 (Kip1, BD
USA, 1/2000), p53 (DO-7, Dako, Heverlee, Belgium,
1/500), EGFR (EGFR 113, Novocastra, Newcastle, UK,
1/25), Her2/Neu (SP-3, Neomarkers, Fremont, CA, USA,
1/100), Ki-67 (MIB-1, Dako, Heverlee, Belgium, 1/200),
cyclin D1 (Neomarkers, Fremont, CA, USA, 1/50), TS
(TS-antibody, kindly provided by Dr. G. W. Aherne,
Sutton, UK, 1/100), b-catenin (17C2, Menarini, Italy, 1/100),
AURKA (JLM-28, Novocastra, Newcastle, UK, 1/50).
Negative control slides were incubated with Antibody
Diluent only. Next, antibody binding was detected by
Powervision Plus system (Immunologic, Duiven, The
Netherlands) for p21, cyclin D1, and b-catenin, EnVision
system (Dako, Heverlee, Belgium) for TS and AURKA,
and BondMax autostainer (Menarini Diagnostics, Val-
kenswaard, The Netherlands) for p27, p53, EGFR, Her2/
Neu and Ki-67. Diaminobenzidine was used as a chromagen
followed by counterstaining with Mayer hematoxylin.
Evaluation of Protein Expression
Immunoreactivity was evaluated on each TMA sample.
For nuclear staining patterns, extent of staining was scored
0 to 4 according to the percentage of positively stained
tumor cells: 0 = positive staining in 0–1%; 1, 1–10%; 2,
11–25%; 3, 26–50%; 4, [50%. Staining intensity was
scored as 0 = no staining or any intensity in less than 10%
of tumor cells; 1, weak; 2, moderate; 3, strong. For cyto-
plasmic immunoreactivity, only staining intensity was
scored. For protein staining in which both percentage and
intensity were assessed, scores were multiplied to produce
a weighted score (0–12) for each TMA sample.8 Mem-
branous staining was scored 0 to 3, analogous to the Her2/
Neu scoring system approved by the U.S. Food and Drug
Administration.9
For p21, p27, p53, and cyclin D1, extent and intensity of
nuclear staining were scored. For Ki-67, b-catenin and
AURKA, only extent of positively stained nuclei was
assessed, because intensity was similar in all positive
nuclei. For Her2/Neu, membranous staining was scored,
for EGFR both membranous and cytoplasmic, and for TS
only cytoplasmic staining was assessed.
For each patient the highest score of protein expression
was used assigned to the 6 tissue sections obtained by the
core biopsies taken from each tumor sample. Specimens
were examined in a blinded fashion without knowledge of
clinical data. To confirm reproducibility, 15% of all sam-
ples were scored a second time by an independent observer.
Assessment of Cutoff Values
For statistical analysis, scores of protein expression were
dichotomized as low or high. Cutoff values for each protein
were based on receiver–operating characteristic (ROC)
curve analysis and maximum predictive value.10 This
analysis produced the following cutoff values: p21-high if
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score is C6, p27-high if score is C6, p53-high if score is 12,
membranous EGFR-high if score is C1, cytoplasmic
EGFR-high if score is 3, Her2/Neu-high if score is C1,
Ki-67-high if score is 4, cyclin D1-high if score is C8,
nuclear b-catenin-high if score is C1, TS-high if score is
C2, and AURKA-high if score is 4.
DNA Isolation
DNA was isolated from formalin-fixed, paraffin-
embedded colon cancer tissues samples. For each tumor,
areas with at least 70% tumor cells were selected from
4-lm sections. Adjacent serial sections of 10 lm were cut,
and macro dissected. DNA was isolated as previously
described (QIAamp microkit; Qiagen, Hilden, Germany).11
DNA concentrations were measured with a Nanodrop-100
spectrophotometer (Isogen, De Meern, The Netherlands).
Microsatellite Instability Analysis
Tumor samples were analyzed for MSI with the MSI
Analysis System, Version 1.2 according to the manufac-
turer’s instructions (Promega, Madison, WI). This PCR-
based assay uses five mononucleotide repeat markers to
determine MSI status. PCR products were separated by
capillary electrophoresis with the ABI 3130 DNA
sequencer and output data were analyzed by the accom-
panying package GeneScan 3100 (Applied Biosystems,
Foster City, CA). Tumors were classified as microsatellite
instable (MSI) when instability was observed for two or
more markers, and microsatellite stable (MSS) when
instability was observed for none or only one marker.
Statistical Analysis
Cohen’s kappa coefficient was used to assess agreement
on scoring immunohistochemical protein expressions.
Differences in proportions between groups were examined
by Pearson’s chi-square test. Survival rates were displayed
and compared by Kaplan-Meier curves and the log rank
test. Multivariable analysis was performed by backward
stepwise logistic regression. A significance level of 0.05
was used. Statistical analysis was performed with SPSS
17.0 (SPSS, Chicago, IL) and R software (R Foundation for
Statistical Computing, Vienna, Austria). The performance
of the regression models was evaluated in terms of dis-
crimination by the area under the ROC curve and the
explained variation. Bootstrapping techniques were used to
correct these measures for optimism to get a more realistic
insight in their performance.
TABLE 1 Clinical and pathologic characteristics of 386 stage II and III
colon cancer patients
Characteristic Overall Stage II Stage III
(n = 386) (n = 226) (n = 160)
Sex
Male 203 (52.6) 114 (50.4) 89 (55.6)
Female 183 (47.4) 112 (49.6) 71 (44.4)
Age (years)
Mean ± SD 71.0 ± 11.9 71.6 ± 11.8 70.1 ± 12.0
Median (range) 73.0 (28.5–94.0) 73.4 (28.5–93.3) 72.4 (34.5–94.0)
Tumor location
Right sided 173 (44.8) 99 (43.8) 74 (46.2)
Left sided 213 (55.2) 127 (56.2) 86 (53.8)
Tumor size (mm)
Mean ± SD 42.2 ± 19.4 43.5 ± 20.6 40.4 ± 17.6
Tumor stage
T1 4 (1.0) – 4 (2.5)
T2 19 (4.9) – 19 (11.9)
T3 325 (84.2) 201 (88.9) 124 (77.5)
T4 38 (9.8) 25 (11.1) 13 (8.1)
Nodal stage
N0 226 (58.5) 226 (100) –
N1 111 (28.8) – 111 (69.4)
N2 49 (12.7) – 49 (30.6)
No. of nodes examined
Mean ± SD 8.9 ± 5.2 8.4 ± 5.4 9.7 ± 4.8
Microsatellite stability statusa
MSS 267 (80.4) 147 (79.5) 120 (81.6)
MSI 65 (19.6) 38 (20.5) 27 (18.4)
Histologic grade
Well 24 (6.2) 18 (8.0) 6 (3.8)
Moderate 302 (78.2) 180 (79.6) 122 (76.3)
Poor 60 (15.5) 28 (12.4) 32 (20.0)
Mucinous differentiation
Yes 82 (21.2) 48 (21.2) 34 (21.3)
No 304 (78.8) 178 (78.8) 126 (78.8)
Ulceration
Present 297 (76.9) 170 (75.2) 127 (79.4)
Absent 89 (23.1) 56 (24.8) 33 (20.6)
Angioinvasion
Present 78 (20.2) 24 (10.6) 54 (33.8)
Absent 308 (79.8) 202 (89.4) 106 (66.3)
Adjuvant chemotherapy
Yes 122 (31.6) 34 (15.0) 88 (55.0)
No 264 (68.4) 192 (85.0) 72 (45.0)
Recurrent disease
Yes 127 (32.9) 53 (23.5) 74 (46.3)
No 259 (67.1) 173 (76.5) 86 (53.8)
Follow-up (months)
Median (range) 57.2 (3.0–148.6) 63.1 (5.3–139.6) 46.9 (3.0–148.6)
Data are presented as n (%) unless otherwise indicated
a Microsatellite instability status was determined in 332 cases
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RESULTS
Clinicopathologic Features and Disease Recurrence
Disease recurrence rate in 386 stage II and III colon
cancer patients was 32.9%. Stage II patients (n = 226) had
disease recurrence in 23.5% of cases, while of stage III
patients (n = 160) 46.3% developed a recurrence
(P \ 0.01) (Table 1).
MSI status could be determined in 332 cases (i.e., 86%
of tumor samples, while attempts to characterize the
remaining 14% failed as a result of insufficient quality of
the formalin-fixed, paraffin-embedded–derived DNA
material). Of these, 267 were MSS (80.4%) and 65 MSI
(19.6%). Recurrent disease developed in 36.3% of patients
with MSS tumors, compared to 24.6% of MSI cases
(P = 0.07). Considering only stage II patients of whom
MSI status was determined (n = 185), 41 out of 147
patients with MSS tumors showed recurrence, compared to
5 out of 38 patients with MSI tumors (27.9% and 13.2%,
respectively, P = 0.06). For stage III patients with deter-
mined MSI status, no significant difference in recurrence
rate was observed between MSI and MSS tumors.
Cell Cycle-associated Proteins and Disease Recurrence
A high level of agreement on immunohistochemical
scores between the two observers was achieved, resulting
in a median (all proteins separately scored) Cohen’s
weighted kappa value: Kw = 0.67 (range 0.49–0.84). The
number of patients with high and low protein expression
levels and disease recurrence rates are listed in Table 2.
Univariate analysis showed low p21, low cyclin D1,
high p53, and high AURKA expression to be significantly
associated with disease recurrence (P = 0.01, P = 0.04,
P \ 0.01, and P \ 0.01, respectively; Fig. 1a–d). p53
expression was inversely associated with p21 (P = 0.02)
and cyclin D1 expression (P \ 0.01).
Stage II Patients Considering only stage II patients
(n = 226), those with p21-low tumors had significantly
more recurrences compared to p21-high tumors (30.1% vs.
15.6%, respectively; P = 0.01; Fig. 1e) and a tendency
toward higher recurrence rate was observed for cyclin D1-
low compared to cyclin D1-high tumors (27.9% vs. 17.8%,
respectively; P = 0.08).
When excluding patients who received adjuvant chemo-
therapy (n = 34) from all stage II patients, p53-high tumors
were associated with more recurrences than p53-low tumors
(32.1% vs. 18.3%, respectively; P = 0.03; Fig. 1f).
Stage III Patients Focussing on stage III patients, high
p53 and high AURKA expression were significantly
associated with disease recurrence (P = 0.02 and
P \ 0.01, respectively; Fig. 2a and b, respectively). For
p53, difference in recurrence rate was mainly attributable
to stage III patients who did not receive adjuvant
chemotherapy (n = 72) as recurrence rate for patients
with p53-high tumors was 59.4% compared to 30.8% for
patients with p53-low tumors (P = 0.02). Disease-free
survival (DFS) of stage III patients with high p53
expressing tumors who received chemotherapy was not
different from those without chemotherapy (P = 0.5). DFS
was also similar between patients with low p53 tumors
receiving chemotherapy and those without chemotherapy
(P = 0.6) (Fig. 2c).
For AURKA, difference in recurrence rate was mainly
attributable to stage III patients who did receive chemo-
therapy as recurrence was observed in AURKA-high
tumors in 54.7%, compared to 17.6% in AURKA-low
tumors (P \ 0.01). DFS of stage III patients with high
AURKA expressing tumors who received chemotherapy
was not different from those without chemotherapy
(P = 0.5). DFS was also similar between patients with low
AURKA tumors receiving chemotherapy and those without
chemotherapy (P = 0.5) (Fig. 2d).
Multivariable analysis included all protein expression
levels, disease stage, tumor location, lymph node yield
[high (C12) vs. low (\12)], MSI status, angioinvasive
growth and chemotherapy treatment. The following fac-
tors are independently associated with disease recurrence:
disease stage [odds ratio (OR) 1.8, 95% confidence
interval (CI) 1.0–3.0], low lymph node yield (OR 1.8,
95% CI 1.0–3.4), angioinvasive growth (OR 3.5, 95% CI
1.8–6.5), AURKA (OR 2.7, 95% CI 1.3–5.6) and p21
(OR 1.6, 95% CI 0.9–2.8). The area under the ROC curve
of this model is 0.72 (0.71 after correction for optimism)
and the explained variation is 20% (17% after correction
for optimism).
Protein Expression and Disease Recurrence Stratified
by MSI Status
Low p21, high p27, high p53, and low cyclin D1
expression were observed in 63.7%, 77.4%, 52.1%, and
91.6% of all (stage II and III) MSS tumors (n = 267),
respectively, and expression rates for these proteins were
significantly different in MSI tumors, for which these rates
were 32.3%, 58.5%, 24.2%, and 67.2%, respectively (all
P values \ 0.01).
In patients with MSS tumors, univariate analysis
revealed high expression of p53 and AURKA to be sig-
nificantly associated with disease recurrence rate
(P = 0.01 and P \ 0.01, respectively; Fig. 3a and b,
respectively).
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Stage II Patients with MSS Tumors When excluding
patients who received adjuvant chemotherapy (n = 24)
from all MSS stage II patients (n = 147), those with p53-
high tumors developed more recurrences than patients with
p53-low tumors, although statistical significance was not
reached (36.7% vs. 21.3%, P = 0.06). Furthermore, those
with p21-low tumors exhibited significantly more
recurrences than patients with p21-high tumors (36.0%
vs. 15.9%, P = 0.02).
Stage III Patients with MSS Tumors In MSS stage III
patients (n = 120), high p53 expression was associated
with worse outcome especially in patients who did not
receive adjuvant chemotherapy (n = 51) as those with p53-
high tumors developed recurrence in 66.7% compared to
25.9% in case of p53-low tumors (P \ 0.01). DFS of stage
III patients with high p53 expressing tumors who received
chemotherapy was not different from those without
chemotherapy (P = 0.2). DFS was also similar between
TABLE 2 Protein expression and recurrence rate in 386 stage II and III colon cancer patients









High 154 25.3 96 15.6 58 41.4
Low 219 37.9 0.01 123 30.1 0.01 96 47.9 0.43
p27
High 278 30.9 166 22.3 112 43.8
Low 101 36.6 0.30 57 28.1 0.38 44 47.7 0.65
p53
High 176 40.3 98 28.6 78 55.1
Low 203 26.6 \0.01 123 20.3 0.15 80 36.3 0.02
EGFR membranous
High 283 32.5 167 24.0 116 44.8
Low 95 34.7 0.69 53 24.5 0.93 42 47.6 0.76
EGFR cytoplasmic
High 240 32.5 146 25.3 94 43.6
Low 138 34.1 0.76 74 21.6 0.54 64 48.4 0.55
Her2/Neu
High 110 27.3 64 21.9 46 34.8
Low 266 34.6 0.17 156 23.7 0.77 110 50.0 0.08
Ki-67
High 267 31.8 157 21.7 110 46.4
Low 117 35.0 0.54 68 27.9 0.31 49 44.9 0.86
Cyclin D1
High 168 26.8 101 17.8 67 40.3
Low 211 36.5 0.04 122 27.9 0.08 89 48.3 0.32
TS
High 223 28.7 141 22.7 82 39.0
Low 160 37.5 0.07 84 23.8 0.85 76 52.6 0.09
b-Catenin (nuclear)
High 137 30.7 86 23.3 51 43.1
Low 241 34.9 0.41 133 24.8 0.79 108 47.2 0.63
AURKA
High 264 36.0 146 24.7 118 50.0
Low 89 19.1 \0.01 62 17.7 0.28 27 22.2 \0.01
For each protein expression analysis, samples were excluded when insufficient amounts of tissue were available for evaluation of protein
expression
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patients with low p53 tumors receiving chemotherapy and
those without chemotherapy (P = 0.5). DFS curves are
displayed in Fig. 4a.
For AURKA, difference in recurrence rates in stage III
patients with MSS tumors was mainly attributable to
patients who did receive adjuvant chemotherapy (AURKA-
high 53.1% recurrence, AURKA-low 20.0% recurrence;
(P = 0.02). DFS of stage III patients with high AURKA
expressing tumors who received chemotherapy was not
different from those without chemotherapy (P = 0.9). DFS
was also similar between patients with low AURKA
tumors receiving chemotherapy and those without chemo-
therapy (P = 0.8). DFS curves are displayed in Fig. 4b.
Patients with MSI Tumors In the total population (stage
II and III) with MSI tumors (n = 65), no significant
associations were found between protein expression and
disease recurrence.
DISCUSSION
In the present study, usefulness of cell cycle-associated
proteins as prognostic markers was investigated in stage II
and III colon cancer. Low p21, low cyclin D1, high p53,




FIG. 2 DFS curves for stage III colon cancer patients according to
protein expression levels of p53 (a, c) and AURKA (b, d).
Stratification to adjuvant chemotherapy (chemotherapy [‘‘chemo’’],
no chemotherapy [‘‘no chemo’’]) (c, d). (c) p53 high, no chemo vs.
p53 low, no chemo (log rank 4.0, P = 0.05). (d) AURKA high,
chemo vs. AURKA low, chemo (log rank 6.1, P = 0.01). Patients
were excluded from protein expression analysis when insufficient
amounts of tissue were available for evaluation of protein expression
levels
FIG. 1 DFS curves for stage II and III colon cancer patients
(n = 386) according to protein expression levels of a p21, b cyclin
D1, c p53, and d AURKA and DFS curves for only stage II patients
(n = 226) according to expression levels of e p21 and f p53 (patients
with adjuvant chemotherapy excluded). Patients were excluded from
protein expression analysis when insufficient amounts of tissue were
available for evaluation of protein expression levels
b
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As the ‘‘guardian of the genome,’’ p53 functions as a
tumor suppressor by inducing temporary cell cycle arrest to
facilitate repair mechanisms when DNA damage occurs or
it can induce apoptosis when damage seems irrepara-
ble.12,13 Loss of these crucial functions leads to replication
of defective DNA, genomic instability and progression to
cancer. Mutation of the p53 gene occurs in over 50% of
human tumors including sporadic colorectal cancer.14,15 It
should be noted that the short half-life of wild-type p53
protein normally renders it undetectable by IHC, and that
high p53 expression is caused by ‘‘mutated p53,’’ which
is due to protein-stabilizing conformational alteration.16
A systematic review on p53 abnormalities in colorectal
cancer underlines that conflicting results have been repor-
ted.17 Concluded was that overall, abnormal p53 has an
adverse effect on outcome in patients with better underlying
prognosis and no effect on outcome in patients treated with
5-fluorouracil-based chemotherapy. The results of the pres-
ent study are in line with these conclusions as high
(presumably mutated) p53 expression was significantly
associated with recurrence in stage II patients who did not
receive adjuvant chemotherapy.
The p21-gene is the primary mediator of p53-induced
cell cycle arrest as p21-protein functions as inhibitor of G1
cyclin-dependent kinases (CDKs) and regulates entry of
cells into S-phase.18 Cells lacking functional p53 express
only low levels of p21. This is supported by the present
study showing a significant association between high,
likely nonfunctional p53 and low p21 levels. Abnormal p21
protein levels have been documented in colon cancer
patients, but mostly in small and heterogeneous patient
populations with contradictory conclusions.19–23 In the
a bFIG. 3 DFS curves for MSS
stage II and III (n = 267) colon
cancer patients according to
protein expression levels of p53
(a) and AURKA (b). Patients
were excluded from protein
expression analysis when
insufficient amounts of tissue
were available for evaluation of
protein expression levels
a b
FIG. 4 DFS curves for stage III MSS patients according to protein
expression levels of p53: (a) and AURKA: (b) stratified to adjuvant
chemotherapy treatment (chemotherapy [‘‘chemo’’], no chemotherapy
[‘‘no chemo’’]). a p53 high, no chemo vs. p53 low, no chemo (log
rank 7.8, P \ 0.01. b AURKA high, chemo vs. AURKA low, chemo
(log rank 4.3, P = 0.04. Patients were excluded from protein
expression analysis when insufficient amounts of tissue were avail-
able for evaluation of protein expression levels
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present study, low p21 expression was independently
associated with recurrent disease, mostly attributable to
stage II patients. We found high p21 expression to be
associated with MSI genotype and this relation is con-
firmed by other studies.23–25
Cyclin D1 plays a key role in cell cycle control, as it
complexes with CDKs in the G1-phase resulting in S-phase
entry.26 Cyclin D1 activation by APC mutation/WNT sig-
naling seems to contribute to colon neoplasia initiation.27
Despite a well-established role of cyclin D1 in cell cycle
progression, previous data on cyclin D1 and clinical out-
come in colon cancer have been conflicting, and most
previous studies had small and heterogeneous study pop-
ulations. Although in two studies cyclin D1 overexpression
has been associated with poor prognosis and in another two
studies with good prognosis, most studies have shown no
prognostic value of cyclin D1 overexpression.19,22,28–31 In
the present study, cyclin D1 overexpression was associated
with improved outcome. The biological background sup-
porting this association remains subject of debate. As
suggested previously, in order to acquire enhanced malig-
nant characteristics, cyclin D1 negative cancers might have
bypassed the necessity of cyclin D1 activation, resulting in
more aggressive behavior than cyclin D1-activated can-
cers.31 Previously, cyclin D1 has been described to be
overexpressed in MSI colorectal cancers, as in the present
study.32
The Aurora kinase family is a collection of highly
related serine/threonine kinases that are key regulators of
mitosis. Aurora has evolved into three related kinases
known as Aurora kinase A, B, and C. The Aurora kinase A
protein (AURKA) is a centrosome-associated protein and
has been implicated in regulatory centrosome function,
spindle assembly, chromosome segregation and cytokine-
sis.33,34 AURKA positively regulates the G2 to M phase of
the cell cycle and activation of AURKA in late G2 is
inhibited by DNA damage.33 Activation of AURKA in
experimental systems confers malignant phenotype by
inducing centrosome amplification and genomic instability,
indicating AURKA as an oncogene.35 The gene for
AURKA is located on chromosome 20q13.2, a region
commonly amplified in malignancies.33,36 Amplification of
AURKA mRNA has been found in many human tumors,
including colorectal cancer.33,37,38
Few studies are available addressing the association
between AURKA and outcome in colorectal cancer
patients. Two studies didn’t find a significant association
between AURKA and survival.39,40 These studies descri-
bed 517 and 200 tissue samples, respectively, both from
stage I to IV colon and rectal cancer patients without
including chemotherapy and radiotherapy in the analysis.39
Another study showed worse survival for patients with
AURKA-high tumors, but the study population was small
(n = 55) and heterogeneous (stage I to IV colon and rectal
cancers).41
In the present study, high AURKA expression was sig-
nificantly associated with recurrence in a large,
homogeneous cohort of colon cancer patients. Many stud-
ies have investigated expression levels of cell cycle
proteins and clinical outcome in colorectal cancer patients
reporting conflicting results.22,42–50 Most studies describe
heterogeneous patient populations without stratification for
tumor localization (colon vs. rectum) and MSI status and
without multivariate analysis. Furthermore, the choice of
scoring method and selection of cutoff values for immu-
noreactivity is rarely described. The present study
described a large, homogeneous cohort stage II and III
colon cancer patients, including MSI status and multivar-
iate analysis. ROC curves were used to select cutoff values
because this is an established method in clinical oncology
to evaluate sensitivity and specificity of diagnostic
tests.51,52 It has proven to be useful in determining clini-
cally relevant thresholds for immunohistochemical tumor
positivity in biomarker studies.10,53 Of course, before these
markers can be used in a clinical setting, validation studies
that use the same immunohistochemical techniques and
scoring methods are necessary to proof generalizability.
In conclusion, in the present study, low p21, high p53,
low cyclin D1, and high AURKA were associated with
disease recurrence in stage II and III colon cancer patients.
These proteins could possibly be used as prognostic
markers to identify patients with high risk of recurrence
and help to decide whether or not adjuvant chemotherapy
should be offered.
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